For appropriate patients with COPD,

START WITH ANORO INSTEAD OF ADVAIR 

ANORO demonstrated superior improvement in lung function vs ADVAIR, an ICS/LABA7

Triangle

A LAMA/LABA vs AN ICS/LABA?

The 2 bronchodilators in ANORO provide nearly 2x the lung function improvement vs ADVAIR, an ICS/ LABA—a single bronchodilator and an inhaled corticosteroid

 

ANORO versus ADVAIR study information
Chart 1 Anoro Vs Advair_updated_mobile

Studied in patients with moderate to severe COPD (GOLD 2 or 3).7

  • DESCRIPTION OF STUDIES

     

    The efficacy and safety of a once-daily dose of ANORO ELLIPTA and a twice-daily dose of ADVAIR DISKUS 250 mcg/​50 mcg were evaluated in 12-week, multicenter, randomized, double-blind, double-dummy, parallel-group studies in patients (mean age range: 63 to 64 years) with COPD with no exacerbations (COPD symptoms requiring oral corticosteroids, antibiotics, and/or hospitalization) in the previous year. At screening, patients had a mean postbronchodilator FEV1 range of 49.4% to 49.5% predicted.

     

    Primary endpoint

    Weighted mean FEV 1 (0-24 hours post-dose on Day 84).

ANORO provided more patients with a ≥100 mL lung function improvement vs an established ICS/LABA7

Proportion of patients achieving an increase in trough FEV1 ≥100 mL above baseline at Day 85
Other endpoint: Endpoint was not adjusted for multiplicity.

 

ANORO versus ADVAIR study data
Chart 2 Anoro Vs Advair_updated_mobile

Studied in patients with moderate to severe COPD (GOLD 2 or 3).7

  • DESCRIPTION OF STUDIES

     

    The efficacy and safety of a once-daily dose of ANORO ELLIPTA and a twice-daily dose of ADVAIR DISKUS 250 mcg/​50 mcg were evaluated in 12-week, multicenter, randomized, double-blind, double-dummy, parallel-group studies in patients (mean age range: 63 to 64 years) with COPD with no exacerbations (COPD symptoms requiring oral corticosteroids, antibiotics, and/or hospitalization) in the previous year. At screening, patients had a mean postbronchodilator FEV1 range of 49.4% to 49.5% predicted.

     

    Primary endpoint

    Weighted mean FEV 1 (0-24 hours post-dose on Day 84).
     

    Other efficacy endpoint

    Proportion of patients achieving an increase of ≥100 mL above baseline in trough FEV1 at Day 85.

     

Adverse events occurring in ≥3% of subjects in the 2 clinical studies7

RANGE OF ADVERSE EVENTS ACROSS THESE STUDIES (%)

ADVERSE EVENTS 

ANORO ELLIPTA

ADVAIR DISKUS

STUDY DB2114930 (n=353) (n=353)
Headache 7% 5%
Nasopharyngitis 5% 2%
STUDY DB2114951 (n=349) (n=348)
Headache 7% 7%
Nasopharyngitis 4% 2%

Safety data are descriptive only. The studies were not powered to compare the safety profiles of the products.

  • DESCRIPTION OF STUDIES

     

    The efficacy and safety of a once-daily dose of ANORO ELLIPTA and a twice-daily dose of ADVAIR DISKUS 250 mcg/​50 mcg were evaluated in 12-week, multicenter, randomized, double-blind, double-dummy, parallel-group studies in patients (mean age range: 63 to 64 years) with COPD with no exacerbations (COPD symptoms requiring oral corticosteroids, antibiotics, and/or hospitalization) in the previous year. At screening, patients had a mean postbronchodilator FEV1 range of 49.4% to 49.5% predicted.

     

    Primary endpoint

    Weighted mean FEV 1 (0-24 hours post-dose on Day 84).